Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: Updated Analysis of the ELIANA Clinical Trial
Stephan A. Grupp(Children's Hospital of Philadelphia), Hidefumi Hiramatsu(Kyoto University), André Baruchel(Université Paris Cité), Christina Peters(Cancer Research Institute of the Slovak Academy of Sciences), Françoise Méchinaud(Hotel Dieu Hospital), Gary Douglas Myers(Baylor College of Medicine), Susana Rives(Hospital Sant Joan de Déu Barcelona), Peter Bader(Goethe University Frankfurt), Eneida R. Nemecek(Oregon Health & Science University), Muna Qayed(Emory University), Lamis Eldjerou, Shannon L. Maude(Children's Hospital of Philadelphia), Heather E. Stefanski(National Marrow Donor Program), Karen Thudium Mueller(Unknown), Joerg Krueger(Hospital for Sick Children), Barbara De Moerloose(Ghent University Hospital), Nicolas Boissel(Inserm), Michael Boyer(Chris O’Brien Lifehouse), Adriana Balduzzi(Azienda Ospedaliera San Gerardo), Gregory A. Yanik(University of Michigan), Jochen Büchner(Goethe University Frankfurt), Eric Bleickardt(Unknown), Theodore W. Laetsch(Children's Hospital of Philadelphia), Henrique Bittencourt(Centre Hospitalier Universitaire Sainte-Justine), Paul L. Martin(Duke University), Michael A. Pulsipher(Primary Children's Hospital), Mimi Leung(Unknown), Kara L. Davis(Stanford Medicine)
Cited by 17
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k